

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include⦠read more
Healthcare
Biotechnology
22 years
USD
Exclusive to Premium users
$220.33
Price+7.21%
$14.81
$29.482b
Large
39.7x
Premium
Premium
+19.0%
EBITDA Margin+12.7%
Net Profit Margin+3.2%
Free Cash Flow Margin+19.0%
EBITDA Margin+12.7%
Net Profit Margin+3.2%
Free Cash Flow Margin$4.804b
+29.4%
1y CAGR+39.2%
3y CAGR+48.4%
5y CAGR$807.988m
+157.5%
1y CAGR+135.7%
3y CAGR+117.0%
5y CAGR$5.92
+154.1%
1y CAGR+133.0%
3y CAGR+115.3%
5y CAGR$1.354b
$5.559b
Assets$4.205b
Liabilities$1.267b
Debt22.8%
1.1x
Debt to EBITDA$542.543m
+16.6%
1y CAGR+335.9%
3y CAGR+278.7%
5y CAGR